Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease
Authors:
Open Access
- 1 October 2002
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 61 (10) , 929-933
Abstract
Objective: To determine whether anti-Ro52 is an independent serum marker in connective tissue disease. Methods: Over a two year period, 1727 consecutive antinuclear antibody (ANA) positive serum samples were analysed in parallel by double immunodiffusion with thymus/spleen nuclear extract and by line immunoassay with recombinant Ro52, recombinant La/SSB, and natural Ro60. Sera that were only reactive towards Ro52 were further analysed by a variety of additional anti-SSA/Ro detection methods and by specific anti-Ro52 and anti-Ro60 assays. Natural purified SSA/Ro was analysed by immunoblot and protein sequencing. Results: Analysis of natural purified SSA/Ro (Immunovision, Springdale, AR) showed only Ro60 and no immunoreactive Ro52. Consequently, assays based on this substrate only identify sera with anti-Ro60 reactivity. Twenty serum samples showed anti-Ro52 without anti-Ro60 and anti-SSB/La on line immunoassay. By additional testing, 2/20 sera were found positive for anti-Ro60 reactivity. The remaining 18 sera were not identified by any of the classical anti-SSA/Ro assays and were considered to be reactive only with Ro52 and not with Ro60. This anti-Ro52 reactivity was confirmed by natural and recombinant Ro52 in 16/18 cases. 12/18 sera corresponded to connective tissue diseases. Conclusion: Anti-Ro52 positive sera without any evidence of anti-Ro60 and anti-La/SSB reactivity can be considered as an independent group that is systematically missed by classical anti-SSA/Ro detection methods owing to a bias towards anti-Ro60 reactivity. The anti-Ro52 sera are precipitin negative, not retrieved by SSA/Ro enzyme linked immunosorbent assays (ELISAs) based on natural SSA/Ro, and show no specific ANA fluorescence staining pattern. These findings together with the clinical data indicate that anti-Ro52 should be considered as an additional and independent serum marker.Keywords
This publication has 13 references indexed in Scilit:
- Sensitivity of the HEp-2000 Substrate for the Detection of Anti-SSA/Ro60 AntibodiesClinical Rheumatology, 2000
- Fine specificity of the autoimmune response to the Ro/SSA and La/SSB ribonucleoproteinsArthritis & Rheumatism, 1999
- The Zn2+Binding Domain of the Human Ro 52 kDa Protein is a Target for Conformation-dependent AutoantibodiesJournal of Autoimmunity, 1998
- Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathyClinical and Experimental Immunology, 1997
- Transfection and Overexpression of the Human 60-kDa Ro/SS-A Autoantigen in HEp-2 CellsClinical Immunology and Immunopathology, 1994
- Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European communityArthritis & Rheumatism, 1993
- In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresisAnalytical Biochemistry, 1992
- Effective separation of the 52 kDa SSA/Ro polypeptide from the 48 kDa SSB/La polypeptide by altering conditions of polyacrylamide gel electrophoresisJournal of Immunological Methods, 1990
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- The 1982 revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1982